DFDA

Labetalol

Treatment for Maternal Hypertensive Disorders

Typical Dosage: 100-400 mg 2-3 times daily

Effectiveness
88%
Safety Score
72%
Clinical Trials
200
Participants
5K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
72
DangerousModerateSafe
Treatment Details
Dosage Range
100-400 mg 2-3 times daily
Time to Effect
30-90 minutes (oral)
Treatment Duration
Until delivery
Evidence Quality
HIGH
Number Needed to Treat (NNT)
5(Treat 5 patients to see 1 additional successful outcome)
Confidence Score
92%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$150
Monitoring:$1,000
Side Effect Mgmt:$200
Total Annual:$1,350
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
QALYs Gained
0.3
Outcome-Based Costs
Cost per Responder
$1,588
Prescription Access Economics
Physician Visit Cost
$1,000/year
Time Cost
$240/year
Travel + wait time
Insurance Admin Cost
$240/year
Prior auth, claims
Rx Price
$150/year
Risk Assessment
Misuse Risk
MODERATE
Missed Diagnosis Risk
LOW
Requires Monitoring
Yes
Needs lab work/checkups
Labetalol Outcomes

for Maternal Hypertensive Disorders

Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+85%
Common Side Effects
Dizziness
+15%
Nausea
+7%
Fatigue
+6%
Scalp tingling
+3%
Fetal bradycardia
+0.5%

Sources:

viamedica.pl
researchgate.net
viamedica.pl

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
1 active trial recruiting for Labetalol in Maternal Hypertensive Disorders

Factors Associated With Blood Pressure Control Failure to Intravenous Labetalol in Severe Preeclampsia

NCT07547046NOT YET RECRUITING
View Study
350 participants
OBSERVATIONAL
Bordeaux, France +13 more
Started: Apr 1, 2026